The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005
Open accessAbstract
The incretin hormones are intestinal polypeptides that enhance postprandial insulin secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid secretion, whereas glucagon-like peptide-1 (GLP-1) was discovered as a result of a systematic search for intestinal insulinotropic products of proglucagon gene expression. The incretin effect is markedly impaired or absent in patients with type 2 diabetes because of decreased secretion of GLP-1 and a loss of the insulinotropic effects of GIP. Metabolic control can be restored or greatly improved by administration of exogenous GLP-1, but this peptide is almost immediately degraded by dipeptidyl peptidase IV (DPP-IV), and therefore has little clinical value. DPP-IV-resistant analogues (incretin mimetics) have been identified or developed, and inhibitors of DPP-IV have also proved effective in protecting endogenous GLP-1 (and GIP) from degradation. Both principles have been tested in clinical studies. The incretin mimetics, administered by sc injection, have demonstrated lasting improvement in HbA(1)c in patients insufficiently treated with conventional oral therapy, and their use has been associated with steady weight loss for up to 2 years. The DPP-IV inhibitors, given once or twice daily by mouth, also appear to provide lasting improvement in HbA(1)c, but are weight-neutral. The first incretin mimetic has reached the market in the US, and applications for approval of the first inhibitors are expected to be filed early in 2006.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The major effect of incretins is the potentiation of glucose-stimulated insulin secretion by pancreatic β-cells [14,15,16,17].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“In addition, GLP-1 was shown to inhibit appetite and food intake, both in healthy individuals [36], and in patients with type 2 diabetes [37].”
BackgroundSelf-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Research works printed but not linked: 4
- Holst JJ, Orskov C, Schwartz TW, Buhl T, Baldissera F (1986) Proglucagon 78-107, a potent insulinotropic hormone from the lower small intestine. Diabetologia 29:549A (Abstract)
- Larsen J, Jallad J, Damsbo P (1996) One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45:233A (Abstract)
- Ehlers MRW, Roderick EH, Schneider RL, Kipnes MS (2002) Continuous subcutaneous infusion of recombinant GLP-1 for 7 days dose-dependently improved glycemic controls in type 2 diabetes. Diabetes 51:A579 (Abstract)
- Nauck M, Hompesch M, Filipczak R et al (2004) Liraglutide as add-on to metformin in type 2 diabetes: significant improvement in glycaemic control with a reduction in body weight compared with glimepiride. Diabetologia 47:A281 (Abstract)
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationDeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532
Metadata
- Authors
- Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Holst, J. J.
- ORCID
- Holst, J. J.
- Venue
- Diabetologia
- Published
- 2006-01-14
- Volume
- 49
- Issue
- 2
- Pages
- 253-260
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2082032596
- Cited by
- 228
- References
- 95
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 5 · 2019: 6 · 2018: 6 · 2017: 5 · 2016: 10 · 2015: 13 · 2014: 7 · 2013: 13 · 2012: 16
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- European Foundation for the Study of Diabetes
- Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, incretins, glucose-dependent insulinotropic polypeptide, proglucagon, type 2 diabetes, insulin secretion, incretin mimetics, DPP-4 inhibitors, dipeptidyl peptidase IV, HbA1c, weight loss, oral antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Intestines, Peptides, Protease Inhibitors, Venoms, Receptors, Glucagon, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. https://app.cochat.ai/papers/10.1007/s00125-005-0107-1
- The paper
- Holst, J. J. (2006). Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. https://doi.org/10.1007/s00125-005-0107-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.